Diabetes and Obesity Program, Garvan Institute of Medical Research, Sydney, New South Wales 2010, Australia.
Mol Cell Biol. 2011 Dec;31(23):4789-800. doi: 10.1128/MCB.05583-11. Epub 2011 Oct 3.
Insulin exerts many of its metabolic actions via the canonical phosphatidylinositide 3 kinase (PI3K)/Akt pathway, leading to phosphorylation and 14-3-3 binding of key metabolic targets. We previously identified a GTPase-activating protein (GAP) for Rac1 called RhoGAP22 as an insulin-responsive 14-3-3 binding protein. Insulin increased 14-3-3 binding to RhoGAP22 fourfold, and this effect was PI3K dependent. We identified two insulin-responsive 14-3-3 binding sites (pSer(16) and pSer(395)) within RhoGAP22, and mutagenesis studies revealed a complex interplay between the phosphorylation at these two sites. Mutating Ser(16) to alanine blocked 14-3-3 binding to RhoGAP22 in vivo, and phosphorylation at Ser(16) was mediated by the kinase Akt. Overexpression of a mutant RhoGAP22 that was unable to bind 14-3-3 reduced cell motility in NIH-3T3 fibroblasts, and this effect was dependent on a functional GAP domain. Mutation of the catalytic arginine of the GAP domain of RhoGAP22 potentiated growth factor-stimulated Rac1 GTP loading. We propose that insulin and possibly growth factors such as platelet-derived growth factor may play a novel role in regulating cell migration and motility via the Akt-dependent phosphorylation of RhoGAP22, leading to modulation of Rac1 activity.
胰岛素通过经典的磷脂酰肌醇 3 激酶 (PI3K)/Akt 途径发挥其许多代谢作用,导致关键代谢靶标的磷酸化和与 14-3-3 的结合。我们之前发现了一种称为 RhoGAP22 的 Rac1 GTP 酶激活蛋白 (GAP) 是一种对胰岛素有反应的 14-3-3 结合蛋白。胰岛素使 14-3-3 与 RhoGAP22 的结合增加了四倍,这种作用依赖于 PI3K。我们在 RhoGAP22 中鉴定了两个对胰岛素有反应的 14-3-3 结合位点(pSer(16)和 pSer(395)),并且突变研究揭示了这两个位点磷酸化之间的复杂相互作用。将 Ser(16)突变为丙氨酸会阻止 RhoGAP22 体内与 14-3-3 的结合,并且 Ser(16)的磷酸化是由 Akt 激酶介导的。表达一种不能与 14-3-3 结合的突变型 RhoGAP22 会降低 NIH-3T3 成纤维细胞的细胞迁移能力,并且这种作用依赖于功能正常的 GAP 结构域。RhoGAP22 的 GAP 结构域中的催化精氨酸的突变增强了生长因子刺激的 Rac1 GTP 加载。我们提出,胰岛素和可能的生长因子(如血小板衍生生长因子)可能通过 Akt 依赖性 RhoGAP22 磷酸化来发挥调节细胞迁移和运动的新作用,从而调节 Rac1 活性。